Why the study?
Left ventricular global longitudinal strain by speckle tracking echocardiography is a sensitive measure of intrinsic myocardial function, but its role as a marker of CMR replacement myocardial fibrosis and the prognostic value of fibrosis-associated thresholds in aortic stenosis required establishment and validation.
Does left ventricular global longitudinal strain (LV-GLS) predict adverse outcomes in patients with moderate-severe aortic stenosis and preserved LVEF?
Does left ventricular global longitudinal strain (LV-GLS) predict adverse outcomes in patients with moderate-severe aortic stenosis and preserved LVEF?
LV-GLS thresholds associated with replacement myocardial fibrosis provide independent prognostic value for risk-stratifying patients with moderate-severe aortic stenosis and preserved LVEF.
Answers are grounded in this paper and cite their sources.
LV-GLS thresholds may mark fibrosis; leaves open prospective validation before replacing CMR in HF risk stratification.
Aims: Left ventricular ejection fraction is the conventional measure used to guide heart failure management, regardless of underlying etiology. Left ventricular global longitudinal strain (LV-GLS) by speckle tracking echocardiography (STE) is a more sensitive measure of intrinsic myocardial function. We aim to establish LV-GLS as a marker of replacement myocardial fibrosis on cardiovascular magnetic resonance (CMR) and validate the prognostic value of LV-GLS thresholds associated with fibrosis. Methods and results: LV-GLS thresholds of replacement fibrosis were established in the derivation cohort: 151 patients (57 ± 10 years; 58% males) with hypertension who underwent STE to measure LV-GLS and CMR. Prognostic value of the thresholds was validated in a separate outcome cohort: 261 patients with moderate-severe aortic stenosis (AS; 71 ± 12 years; 58% males; NYHA functional class I–II) and preserved LVEF ≥50%. Primary outcome was a composite of cardiovascular mortality, heart failure hospitalization, and myocardial infarction. In the derivation cohort, LV-GLS demonstrated good discrimination (c-statistics 0.74 [0.66–0.83]; P < 0.001) and calibration (Hosmer-Lemeshow χ2 = 6.37; P = 0.605) for replacement fibrosis. In the outcome cohort, 47 events occurred over 16 [3.3, 42.2] months. Patients with LV-GLS > −15.0% (corresponding to 95% specificity to rule-in myocardial fibrosis) had the worst outcomes compared to patients with LV-GLS < −21.0% (corresponding to 95% sensitivity to rule-out myocardial fibrosis) and those between −21.0 and −15.0% (log-rank P < 0.001). LV-GLS offered independent prognostic value over clinical variables, AS severity and echocardiographic LV mass and E/e′. Conclusion: LV-GLS thresholds associated with replacement myocardial fibrosis is a novel approach to risk-stratify patients with AS and preserved LVEF.
No takes yet. Share an insight, caveat, or question.
Le et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: